The use of a h3r inverse agonist for the treatment of excessive daytime sleepiness associated with parkinson's disease (PD)

Abstract

The invention relates to the use of Compound (I), as defined herein, or pharmaceutically acceptable salt thereof, in the treatment of excessive daytime sleepiness associated with Parkinson's disease.

Description

technical field [0001] The present invention relates to the use of compound (I) as defined herein, or a pharmaceutically acceptable salt thereof, for the treatment of excessive daytime sleepiness associated with Parkinson's disease. Background technique [0002] Parkinson's disease (PD) is a slowly progressive neurodegenerative disorder caused by degeneration of dopaminergic neurons in the substantia nigra of the brain, affecting approximately 1% of those over the age of 60 (Rodrigues, T.M. et al., Parkinson and related disorders [Parkinson's Disease and Related Disorders], 2016, 27: 25-34). Motor symptoms associated with PD include muscle stiffness, akinesia, and dystonia. In addition, people with Parkinson's disease often have nonmotor symptoms such as sleep disturbances [eg, excessive daytime sleepiness (EDS)], and impaired cognitive functioning [eg, deficits in attention, executive function, learning, and visuospatial] , fatigue, olfactory dysfunction, and autonomic dy...

AI Technical Summary

Problems solved by technology

A clinical trial showed that two weeks of treatment with 100–200 mg daily modafinil improved the Epworth Sleepiness Scale score, but not sleep latency in the maintenance of wakefulness test [ie, reference (1) above], whereas Another trial of modafinil 200-400 mg daily for 4 weeks showed no improvement in Epworth Sleepiness Scale scores [ie, supra, reference (2)]

Images